What happens after referral? Completion rates of genetic counseling evaluations in breast cancer patients

Author(s):  
Daniela Ochoa ◽  
Christopher Jean-Louis ◽  
Krista Stephenson ◽  
Margaret Woods ◽  
Jill Kelsey ◽  
...  
2020 ◽  
Vol 231 (4) ◽  
pp. S44-S45
Author(s):  
Daniela Alessandra Ochoa ◽  
Margaret Nicole Woods ◽  
Krista Stephenson ◽  
Ronda Shirletta Henry-Tillman

2012 ◽  
Vol 19 (13) ◽  
pp. 4003-4011 ◽  
Author(s):  
Juliette Christie ◽  
Gwendolyn P. Quinn ◽  
Teri Malo ◽  
Ji-Hyun Lee ◽  
Xiuhua Zhao ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 1579-1579
Author(s):  
Sonya Reid-Lawrence ◽  
Tuya Pal ◽  
Ingrid A. Mayer ◽  
Xiao-Ou Shu ◽  
Ann Tezak ◽  
...  

1579 Background: Per national practice guidelines, pre-test genetic counseling (GC) through a board-certified or credentialed genetics health professional (GHP) is recommended when testing for hereditary cancer. We sought to compare differences in rates of pre-test GC among young breast cancer (BC) patients tested with or without GHP involvement across three racial groups (Black, Hispanic and non-Hispanic white (NHW)). Methods: A population-based sample of Black, Hispanic and NHW women diagnosed with invasive BC ≤ age 50 from 2009 to 2012 were recruited through the Florida State Cancer Registry. Participants were asked to complete a baseline questionnaire and release medical records for verification of clinical information and genetic testing. We compared the rates of pre-test GC across racial groups in women tested with or without GHP involvement using Analysis of Variance. Multivariate logistic regression analysis was also conducted to adjust for potential confounders. Results: Of 1618 participants, 828 had genetic testing based on medical records and/or self-reported on their questionnaire. There were 170 (20.5%) with GHP involvement (either through consultation and/or test ordering) and the remaining 658 women (79.5%) had no documentation of GHP involvement. Among patients tested without GHP involvement, rates of pre-test GC were significantly lower among Black women (34.8%) compared to Hispanics (80%) and NHW (78.7%) (p < 0.001). In contrast, among those with GHP involvement, rates of pre-test GC were similar among Black (89.7%), Hispanic (81.1%) and NHW (84.6%) (p = 0.89). Conclusions: Our results suggest that among young breast cancer patients tested for hereditary cancer without GHP involvement, Blacks were significantly less likely to receive pre-test GC, compared to the other two groups. In contrast, rates of pre-test GC among those with GHP involvement were similar across all groups. These results suggest a disparity in receipt of pre-test GC (which is standard of care per national guidelines) among Blacks tested without GHP involvement. These findings are concerning given the need to offer guideline-adherent care to all patients receiving hereditary cancer testing.


2016 ◽  
Vol 15 (2) ◽  
pp. 163-171 ◽  
Author(s):  
J. E. Baars ◽  
A. M. van Dulmen ◽  
M. E. Velthuizen ◽  
E. B. M. Theunissen ◽  
B. C. Vrouenraets ◽  
...  

2016 ◽  
Vol 102 (1) ◽  
pp. 45-50 ◽  
Author(s):  
Nicla La Verde ◽  
Fabio Corsi ◽  
Anna Moretti ◽  
Bernard Peissel ◽  
Davide Dalu ◽  
...  

2009 ◽  
Vol 16 (7) ◽  
pp. 1973-1981 ◽  
Author(s):  
Susan T. Vadaparampil ◽  
Gwendolyn P. Quinn ◽  
Cheryl A. Miree ◽  
Jennifer Brzosowicz ◽  
Bradford Carter ◽  
...  

Tumor Biology ◽  
2017 ◽  
Vol 39 (2) ◽  
pp. 101042831769430 ◽  
Author(s):  
Mina Darooei ◽  
Subhadra Poornima ◽  
Bibi Umae Salma ◽  
Gayatri R Iyer ◽  
Akhilesh N Pujar ◽  
...  

Global burden of breast cancer is expected to increase to >2 million new cases every year by 2030 and 10% of these are likely to have hereditary breast and ovarian cancer syndrome. Identifying these individuals by pedigree and BRCA1/2 mutation analyses will enable us to offer targeted mutation testing and appropriate counseling. This study from a tertiary care hospital showed that of the 127 breast cancer patients on treatment during 2014–2015, 24 of them fulfilled the criteria of hereditary breast and ovarian cancer syndrome after detailed verbal autopsy and pedigree analysis, and BRCA1 and 2 next-generation sequencing done after pre-test counseling revealed mutations in 13 cases (54%), these included 9 BRCA1 mutations (69%) and 4 BRCA2 mutation (31%). Subsequent post-test counseling recommended targeted mutation analysis for 64 high-risk members in these 13 families with pathogenic mutations, which will help in surveillance for early detection, appropriate management, and prevention of the disease by decreasing the burden to both family and nation. Results from this preliminary study highlight the importance of genetic counseling, pedigree analysis, and genetic testing. It can be recommended that all oncology units should have a genetic counseling service for providing appropriate support to oncologists, patients, and families to prevent unnecessary testing; however, breast cancer screening program is incomplete without evaluating for hereditary breast and ovarian cancer syndrome.


Sign in / Sign up

Export Citation Format

Share Document